By Doug Fine
I missed out on an $8,000 one-day profit several weeks ago when I declined an opportunity to invest in British-based GW Pharmaceuticals, which subsequently went public as GWPH on NASDAQ. I could’ve got in at $1. The stock ended its first day of trading around $9, which is about where it’s trading today. (Pause while I absorb a feeling in my gut that I hope is pride but might be fiscal pain.) The purpose of this column is not to speak for or against GW Pharmaceuticals or its cannabis-based products, but rather to elucidate the issues that caused me to err, for now, on the side of whole plant versus concentrated cannabis prescription.